GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

  • You are here:
  • Home
  • Reports
  • GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

The global non-alcoholic steatohepatitis (NASH) biomarker market is projected to register a CAGR of 20.65% by 2028, generating a revenue of $3545.9 million. The base year considered for the market study is 2020, and the forecast years are from 2021 to 2028. Non-alcoholic steatohepatitis (NASH) is a destructive form of non-alcoholic fatty liver disease (NAFLD) and often progress to more severe disorders, such as cirrhosis and hepatocellular carcinoma.

GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

Global Non-alcoholic Steatohepatitis (Nash) Biomarker Market by Type (Serum Biomarker, Hepatic Fibrosis Biomarker, Apoptosis Biomarker, Oxidative Stress Biomarker, Other Types) by End-user (Pharma & Cro Industry, Diagnostic Lab, Academic Research Key, Hospital) and by Geography

Request free sample

The global non-alcoholic steatohepatitis (NASH) biomarker market is projected to register a CAGR of 20.65% by 2028, generating a revenue of $3545.9 million. The base year considered for the market study is 2020, and the forecast years are from 2021 to 2028.

Non-alcoholic steatohepatitis (NASH) is a destructive form of non-alcoholic fatty liver disease (NAFLD) and often progress to more severe disorders, such as cirrhosis and hepatocellular carcinoma.

To learn more about this report, request a free sample copy

Key factors propelling the global non-alcoholic steatohepatitis (NASH) biomarker market growth:

  • Growing NASH affected population
  • Surging prevalence of obesity and diabetes
    • The increasing incidence and prevalence of obesity have surged drastically over the past decade.
    • As per the World Health Organization (WHO) report published in 2020, around 1.9 billion adults, aged 18 years and older, were overweight in 2016.
    • NAFLD is associated with several metabolic comorbidities, including obesity, thereby anticipated to boost the market growth.
  • Increasing occurrence of chronic diseases
  • Surging awareness related to non-alcoholic fatty liver disease

Major growth restraining factors:

  • Side-effects and risks associated with NASH therapeutics
    • The side effects of using NASH therapeutics in clinical trials include nausea, headache, fever, and loss of appetite, among others.
    • As a result, the prevailing side-effects are likely to hinder the market growth.
  • Lack of specialized diagnostic test related to non-alcoholic fatty liver disease (NAFLD)

The report scope of the global non-alcoholic steatohepatitis (NASH) biomarker market includes the segmentation analysis of type and end-user. One of these segments is further classified to provide a detailed analysis of the studied market.

Market by Type:

  • Serum Biomarker
    • The serum biomarker segment, under the type category, held the largest market share in 2020.
    • Serum biomarkers include circulating microRNAs, capable of controlling transcription and translation of various genes.
    • They are most commonly preferred for disease identification, on account of their stable nature and coverage in almost all body fluids.
  • Hepatic Fibrosis Biomarker
    • The hepatic fibrosis biomarker is the fastest-growing type.
    • Hepatic fibrosis biomarkers are used as a non-invasive marker for detecting chronic liver diseases. These include, chronic hepatitis C (HCV), non-alcoholic fatty liver diseases (NAFLD), chronic hepatitis B (HBV), and alcoholic fatty liver diseases (ALD).
  • Apoptosis Biomarker
  • Oxidative Stress Biomarker
  • Other Types

Geographically, the global non-alcoholic steatohepatitis (NASH) biomarker market has been segmented based on four major regions, which includes:

  • North America: The United States and Canada
    • North America is set to dominate the global market by 2028.
    • Non-alcoholic fatty liver disease (steatohepatitis) is considered the region’s most common form of chronic liver disease.
    • According to a study conducted by Intermountain Healthcare researchers, on the economic impact of the condition, non-alcoholic fatty liver diseases affect approximately 100 million Americans, annually.
  • Europe: The United Kingdom, Germany, Italy, France, Belgium, Russia, Poland, and Rest of Europe
  • Asia Pacific: India, Australia & New Zealand, China, South Korea, Japan, Thailand, Indonesia, Vietnam, and Rest of Asia Pacific
    • The Asia Pacific is the fastest-growing region across the global market.
    • Key factors, such as improvements within the healthcare infrastructure, an upsurge in the prevalence of NASH, improvement in economic conditions, and the rising diagnosis rate, are expected to drive the growth of the non-alcoholic steatohepatitis (NASH) market in the Asia Pacific.
  • Rest of World: Latin America, the Middle East & Africa

Major market players operating in the global non-alcoholic steatohepatitis (NASH) biomarker market: 

  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Merck & Co
  • Novartis AG
  • Pfizer Inc
  • Others

Key strategies adopted by some of these companies:

In October 2020, Novartis announced a collaboration with Molecular Partners to develop two DARPin therapies designed for potential use against COVID-19. In July 2020, Pfizer and BioNtech announced an agreement with the United States Government for up to 600 million doses of an mRNA-based vaccine candidate against Sars-Cov-2.

Key findings of the global non-alcoholic steatohepatitis (NASH) biomarker market:

  • Lucrative growth opportunities across developing economies accelerate market growth.
  • Higher unmet medical needs bolster the demand for effective NASH therapeutics.
  • The growing demand for non-invasive diagnostics tools and surging patient awareness levels are anticipated to drive the development of NASH biomarkers.

 

Frequently Asked Questions & Answers (FAQs):

  • How will developments in research strengthen the global non-alcoholic steatohepatitis (NASH) biomarker market growth?

A: Several promising signs of progress in research and developments (R&D), such as enhanced non-invasive diagnostic biomarkers, improved in-vivo liver models, and a better understanding of the disease’s mechanisms, are projected to drive the market growth.

  • What is the role of novel agents within the global non-alcoholic steatohepatitis (NASH) biomarker market?

A: NASH is rapidly emerging as the most common cause of liver cirrhosis. As a result, novel agents possess tremendous potential due to limited treatment focused on medical weight loss.

  • How do non-invasive methods help in the proliferation of the global non-alcoholic steatohepatitis (NASH) biomarker market?

A: There is a growing interest in recognizing the presence of steatohepatitis with the help of a variety of non-invasive methods and algorithms such as transient elastography and using MR or ultrasound technology. These approaches can identify patients with advanced fibrosis.

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    •    KEY DRIVERS
      • GROWING NASH AFFECTED POPULATION
      • SURGING PREVALENCE OF OBESITY AND DIABETES
      • INCREASING OCCURRENCE OF CHRONIC DISEASES
      • SURGING AWARENESS OF NON-ALCOHOLIC FATTY LIVER DISEASE
    •    KEY RESTRAINTS
      • SIDE-EFFECTS AND RISKS ASSOCIATED WITH NASH THERAPEUTICS
      • LACK OF SPECIALIZED DIAGNOSTIC TEST FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
  1. KEY ANALYTICS
    •    PORTER’S FIVE FORCES ANALYSIS
      • THREAT OF NEW ENTRY
      • THREAT OF SUBSTITUTION
      • BUYER’S POWER
      • SUPPLIER’S POWER
      • COMPETITIVE RIVALRY
    • IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • KEY INVESTMENT INSIGHTS
  2. MARKET BY TYPE
    • SERUM BIOMARKER
    • HEPATIC FIBROSIS BIOMARKER
    • APOPTOSIS BIOMARKER
    • OXIDATIVE STRESS BIOMARKER
    • OTHER TYPES
  3. MARKET BY END-USER
    • PHARMA & CRO INDUSTRY
    • DIAGNOSTIC LAB
    • ACADEMIC RESEARCH KEY
    • HOSPITAL
  4. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      •    COUNTRY ANALYSIS
        • THE UNITED STATES
        • CANADA
    •     EUROPE
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      •    COUNTRY ANALYSIS
        • GERMANY
        • FRANCE
        • THE UNITED KINGDOM
        • ITALY
        • RUSSIA
        • BELGIUM
        • POLAND
        • REST OF EUROPE
    •     ASIA PACIFIC
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      •    COUNTRY ANALYSIS
        • CHINA
        • JAPAN
        • AUSTRALIA & NEW ZEALAND
        • INDIA
        • SOUTH KOREA
        • THAILAND
        • INDONESIA
        • VIETNAM
        • REST OF ASIA PACIFIC
    •     REST OF WORLD
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGE
      • KEY PLAYERS
      •    REGIONAL ANALYSIS
        • LATIN AMERICA
        • MIDDLE EAST & AFRICA
  1. COMPETITIVE LANDSCAPE
    •    KEY STRATEGIC DEVELOPMENTS
      • MERGER & ACQUISITIONS
      • PRODUCT LAUNCH & DEVELOPMENTS
      • PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
      • BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
    •    COMPANY PROFILE
      • ALLERGAN PLC (ACQUIRED BY ABBVIE)
      • ASTRAZENECA
      • BRISTOL -MYERS SQUIBB COMPANY
      • GENFIT SA
      • GILEAD SCIENCES, INC
      • MADRIGAL PHARMACEUTICALS
      • MERCK & CO
      • NOVARTIS AG
      • NOVO NORDISK
      • PFIZER INC
      • SIEMENS HEALTHINEERS
      • VIKING THERAPEUTICS
      • ZYDUS CADILA

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER

TABLE 2: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 3: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 4: GLOBAL SERUM BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 5: GLOBAL SERUM BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 6: GLOBAL HEPATIC FIBROSIS BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 7: GLOBAL HEPATIC FIBROSIS BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 8: GLOBAL APOPTOSIS BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 9: GLOBAL APOPTOSIS BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 10: GLOBAL OXIDATIVE STRESS BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 11: GLOBAL OXIDATIVE STRESS BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 12: GLOBAL OTHER TYPES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 13: GLOBAL OTHER TYPES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 14: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 15: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 16: GLOBAL PHARMA & CRO INDUSTRY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 17: GLOBAL PHARMA & CRO INDUSTRY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 18: GLOBAL DIAGNOSTIC LAB MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 19: GLOBAL DIAGNOSTIC LAB MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 20: GLOBAL ACADEMIC RESEARCH KEY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 21: GLOBAL ACADEMIC RESEARCH KEY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 22: GLOBAL HOSPITAL MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 23: GLOBAL HOSPITAL MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 24: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 25: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 26: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 27: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 28: LEADING PLAYERS OPERATING IN NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET

TABLE 29: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 30: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 31: LEADING PLAYERS OPERATING IN EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET

TABLE 32: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 33: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 34: LEADING PLAYERS OPERATING IN ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET

TABLE 35: REST OF WORLD NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 36: REST OF WORLD NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 37: LEADING PLAYERS OPERATING IN REST OF WORLD NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET

LIST OF FIGURES

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, IN 2020

FIGURE 6: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 7: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 8: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 9: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 10: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2028 (IN $ MILLION)

FIGURE 11: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, IN 2020

FIGURE 12: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2028 (IN $ MILLION)

FIGURE 13: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2028 (IN $ MILLION)

FIGURE 14: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2028 (IN $ MILLION)

FIGURE 15: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2028 (IN $ MILLION)

FIGURE 16: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 17: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 18: CANADA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 19: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 20: GERMANY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 21: FRANCE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 22: UNITED KINGDOM NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 23: ITALY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 24: RUSSIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 25: BELGIUM NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 26: POLAND NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 27: REST OF EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 28: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 29: CHINA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 30: JAPAN NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 31: AUSTRALIA & NEW ZEALAND NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 32: INDIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 33: SOUTH KOREA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 34: THAILAND NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 35: INDONESIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 36: VIETNAM NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 37: REST OF ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 38: REST OF WORLD NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)

FIGURE 39: LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 40: MIDDLE EAST & AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

  1. MARKET BY TYPE
    • SERUM BIOMARKER
    • HEPATIC FIBROSIS BIOMARKER
    • APOPTOSIS BIOMARKER
    • OXIDATIVE STRESS BIOMARKER
    • OTHER TYPES
  2. MARKET BY END-USER
    • PHARMA & CRO INDUSTRY
    • DIAGNOSTIC LAB
    • ACADEMIC RESEARCH KEY
    • HOSPITAL
  3. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      •    COUNTRY ANALYSIS
        • THE UNITED STATES
        • CANADA
    •     EUROPE
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      •    COUNTRY ANALYSIS
        • GERMANY
        • FRANCE
        • THE UNITED KINGDOM
        • ITALY
        • RUSSIA
        • BELGIUM
        • POLAND
        • REST OF EUROPE
    •     ASIA PACIFIC
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      •    COUNTRY ANALYSIS
        • CHINA
        • JAPAN
        • AUSTRALIA & NEW ZEALAND
        • INDIA
        • SOUTH KOREA
        • THAILAND
        • INDONESIA
        • VIETNAM
        • REST OF ASIA PACIFIC
    •     REST OF WORLD
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGE
      • KEY PLAYERS
      •    REGIONAL ANALYSIS
        • LATIN AMERICA
        • MIDDLE EAST & AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now